Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, 130021, People's Republic of China.
Drug Des Devel Ther. 2022 Mar 14;16:665-684. doi: 10.2147/DDDT.S348055. eCollection 2022.
Recent clinical guidelines have emphasized the importance of screening for cognitive impairment in older adults with diabetes, however, there is still a lack of understanding about the drug therapy. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are widely used in the treatment of type 2 diabetes and potential applications may include the treatment of obesity as well as the adjunctive treatment of type 1 diabetes mellitus in combination with insulin. Growing evidence suggests that GLP-1 RA has the potential to treat neurodegenerative diseases, particularly in diabetes-related Alzheimer's disease (AD) and Parkinson's disease (PD). Here, we review the molecular mechanisms of the neuroprotective effects of GLP-1 RA in diabetes-related degenerative diseases, including AD and PD, and their potential effects.
最近的临床指南强调了对老年糖尿病患者进行认知障碍筛查的重要性，然而，对于药物治疗仍缺乏了解。胰高血糖素样肽 1 受体激动剂 (GLP-1 RAs) 广泛用于治疗 2 型糖尿病，其潜在应用可能包括治疗肥胖症以及与胰岛素联合治疗 1 型糖尿病。越来越多的证据表明，GLP-1 RA 具有治疗神经退行性疾病的潜力，特别是与糖尿病相关的阿尔茨海默病 (AD) 和帕金森病 (PD)。在这里，我们综述了 GLP-1 RA 在糖尿病相关退行性疾病（包括 AD 和 PD）中的神经保护作用的分子机制及其潜在作用。
